16:09 EST Cartesian Therapeutics (RNAC) files $400M mixed securities shelf
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright
- Cartesian Therapeutics Reports Promising Phase 2b Trial Results
- Cartesian Therapeutics reports positive updated Phase 2b results in myasthenia
- Needham biotech analyst holds an analyst/industry conference call
- Cartesian to present updated data from Phase 2b trial of Descartes-08